Cochrane · systematic review · CD013479
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
Bergman, H, Buckley, BS, Villanueva, G, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
19
No studies
11
Included studies
NR
No studies 11 · 36.7%Ungraded 0 · 0%Very low 3 · 10%Low 6 · 20%Moderate 6 · 20%High 4 · 13.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Two doses of HPV vaccine compared with three doses of HPV vaccine in 9‐ to 15‐year‐old females
Population: 9‐ to 15‐year‐old females
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical and harms outcomes* Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | NR | No studies |
Antibody response (immunogenicity) Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | 4 studies · 45 participants | Moderate Downgraded: imprecision, indirectness |
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | NR | No studies |
High‐grade cervical, vulval, and vaginal disease Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | NR | No studies |
Overall local/injection site adverse events Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | NR | No studies |
Overall systemic events and general symptoms Two doses of HPV vaccine vs three doses of HPV vaccine | no estimate extracted | NR | No studies |
Serious adverse events at up to 5‐year Two doses of HPV vaccine vs three doses of HPV vaccine | OR 1.03 [0.64, 1.66] | 4 studies · 2317 participants | Very low Downgraded: imprecision |
Mortality at up to 5‐year Two doses of HPV vaccine vs three doses of HPV vaccine | OR 0.33 [0.01, 8.19] | 3 studies · 1797 participants | Low Downgraded: imprecision |
Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9‐ to 14‐year‐old females and males
Population: 9‐ to 14‐year‐old females and males
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical and harms outcomes* Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | NR | No studies |
Antibody response (geometric mean titre) Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | 2 studies · 16 participants | Moderate Downgraded: imprecision, indirectness |
Invasive cervical, vaginal, vulval, anal, or penile cancer Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | NR | No studies |
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | NR | No studies |
Overall local/injection site adverse events Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | NR | No studies |
Overall systemic events and general symptoms Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | NR | No studies |
Serious adverse events at up to 5‐year Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | OR 1.15 [0.55, 2.41] | 1 study · 481 participants | Very low Downgraded: imprecision |
Mortality at up to 5‐year Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval | no estimate extracted | 1 study · 481 participants | Low Downgraded: imprecision, indirectness |
Three doses HPV vaccine compared with control in 10‐ to 26‐year‐old males
Population: 10‐ to 26‐year‐old males
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Invasive anal or penile cancer Three doses HPV vaccine vs control | no estimate extracted | NR | No studies |
Penile or anal intraepithelial neoplasia at up to 3‐year Three doses HPV vaccine vs control | Rate ratio 0.17 [0.01, 3.27] | 1 study · 2805 participants | Low Downgraded: imprecision, indirectness |
External genital lesions (any genotype) at up to 3‐year Three doses HPV vaccine vs control | Rate ratio 0.16 [0.07, 0.38] | 1 study · 2545 participants | Moderate Downgraded: imprecision |
Anogenital warts at up to 3‐year Three doses HPV vaccine vs control | Rate ratio 0.11 [0.03, 0.38] | 1 study · 2805 participants | Moderate Downgraded: imprecision |
Overall local/injection site adverse events at 15‐day Three doses HPV vaccine vs control | RR 1.12 [1.06, 1.18] | 1 study · 3895 participants | High |
Overall systemic events and general symptoms at 15‐day Three doses HPV vaccine vs control | RR 0.99 [0.9, 1.08] | 2 studies · 5008 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events at up to 3‐year Three doses HPV vaccine vs control | OR 1.48 [0.15, 14.46] | 1 study · 270 participants | Very low Downgraded: imprecision, indirectness |
Mortality at up to 3‐year Three doses HPV vaccine vs control | no estimate extracted | 1 study · 270 participants | Low Downgraded: imprecision, indirectness |
Nonavalent HPV vaccine compared with quadrivalent HPV vaccine in 9‐ to 26‐year‐old females and males
Population: 9‐ to 26‐year‐old females and males
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer at up to 4.5‐year Nonavalent HPV vaccine vs quadrivalent HPV vaccine | OR 1 [0.85, 1.16] | 1 study · 13753 participants | High |
High‐grade cervical, vulval, and vaginal disease at up to 4.5‐year Nonavalent HPV vaccine vs quadrivalent HPV vaccine | OR 0.99 [0.85, 1.15] | 1 study · 14054 participants | High |
Overall local/injection site adverse events at 15‐day Nonavalent HPV vaccine vs quadrivalent HPV vaccine | RR 1.07 [1.05, 1.08] | 3 studies · 15863 participants | High |
Overall systemic events and general symptoms at 15‐day Nonavalent HPV vaccine vs quadrivalent HPV vaccine | RR 1.01 [0.98, 1.04] | 3 studies · 15863 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events at up to 4.5‐year Nonavalent HPV vaccine vs quadrivalent HPV vaccine | OR 0.6 [0.14, 2.61] | 3 studies · 15863 participants | Low Downgraded: imprecision, indirectness |
Mortality at up to 4.5‐year Nonavalent HPV vaccine vs quadrivalent HPV vaccine | OR 1.2 [0.37, 3.94] | 3 studies · 15248 participants | Low Downgraded: imprecision, indirectness |